Day One Biopharmaceuticals
DAWN
DAWN
125 hedge funds and large institutions have $818M invested in Day One Biopharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.34% more ownership
Funds ownership: 81.84% → 83.18% (+1.3%)
36% less capital invested
Capital invested by funds: $1.29B → $818M (-$468M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
125
Holding in Top 10
2
Calls
$1.35M
Puts
$394K
Top Buyers
| 1 | +$25.6M | |
| 2 | +$12.5M | |
| 3 | +$10.9M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$7.53M |
| 5 |
Goldman Sachs
New York
|
+$6.89M |
Top Sellers
| 1 | -$34.2M | |
| 2 | -$21.4M | |
| 3 | -$20.7M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.93M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.92M |